Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cytokinetics Inc (NASDAQ:CYTK)

7.85
BATS BZX Real-Time Price
As of 2:09pm ET
 -0.60 / -7.10%
Today’s Change
7.00
Today|||52-Week Range
17.20
-35.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$425.7M

Company Description

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Contact Information

Cytokinetics, Inc.
280 East Grand Avenue
South San Francisco California 94080
P:(650) 624-3000
Investor Relations:
(650) 624-3060

Employees

Shareholders

Individual stakeholders6.07%
Other institutional44.32%
Mutual fund holders43.44%

Top Executives

Robert I. BlumPresident, Chief Executive Officer & Director
Ching JawChief Financial Officer & Senior Vice President
Fady Ibraham MalikExecutive Vice President-Research & Development
Andy WolffChief Medical Officer & Senior Vice President
Bonnie A. CharpentierSenior VP-Regulatory Affairs & Compliance